{"entity":{"id":"cblc","kind":"target","name":"CBLC","aka":["Cbl proto-oncogene C","E3 ubiquitin-protein ligase CBL-C","CBL-3","CBL-SL","RNF57"],"tldr":"CBLC (E3 ubiquitin-protein ligase CBL-C) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","summary":"Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Functionally coupled with the E2 ubiquitin-protein ligases UB2D1, UB2D2 and UB2D3. Regulator of EGFR mediated signal transduction; upon EGF activation, ubiquitinates EGFR.\n\nCIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Olaparib.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:15961","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15961"},{"label":"UniProt Q9ULV8","url":"https://www.uniprot.org/uniprotkb/Q9ULV8/entry"},{"label":"NCBI Gene 23624","url":"https://www.ncbi.nlm.nih.gov/gene/23624"},{"label":"Ensembl ENSG00000142273","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000142273"}],"tags":["cancer-genes-wave"],"related":["civic"],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 1 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"CBLC","role":["drug-target","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:15961","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:15961","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q9ULV8","url":"https://www.uniprot.org/uniprotkb/Q9ULV8/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene CBLC","url":"https://civicdb.org/features/9705","note":"1 evidence items, 0 assertions, 1 variants; diseases: Breast Carcinoma (GraphQL API, CC0)"}],"hgnc":"HGNC:15961","ensembl":"ENSG00000142273","uniprot":"Q9ULV8","entrez":"23624","biology":"Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Functionally coupled with the E2 ubiquitin-protein ligases UB2D1, UB2D2 and UB2D3. Regulator of EGFR mediated signal transduction; upon EGF activation, ubiquitinates EGFR. Isoform 1, but not isoform 2, inhibits EGF stimulated MAPK1 activation. Promotes ubiquitination of SRC phosphorylated at 'Tyr-419'. In collaboration with CD2AP may act as regulatory checkpoint for Ret signalling by modulating the rate of RET degradation after ligand activation; CD2AP converts it from an inhibitor to a promoter of RET degradation; the function limits the potency of GDNF on neuronal survival. Locus 19q13.32 (HGNC).","whereFound":["Breast cancer: CIViC evidence names this disease"],"targetClass":"enzyme","prevalence":[]},"route":"/targets/cblc/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"}],"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}]}}